Pulmatrix (PULM) Change in Account Payables (2014 - 2026)
Pulmatrix (PULM) posted Change in Account Payables of $379000.0 for Q1 2026, up 86.7% sequentially from $203000.0 in Q4 2025, and up 349.34% YoY from $84345.5 in Q1 2025.
Pulmatrix (PULM) Change in Account Payables (2014 - 2026) Analysis & Trends
Pulmatrix has reported Change in Account Payables for 13 years, with the latest figure at $379000.0 in Q1 2026.
- Quarterly Change in Account Payables rose 349.34% year-over-year to $379000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6000.0 (up 90.62% YoY) and the FY2025 annual result came in at -$537000.0, up 51.45% from the prior year.
- Change in Account Payables grew to $379000.0 in Q1 2026 per PULM's latest filing, from $203000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $1.2 million in Q4 2023 and troughed at -$1.2 million in Q1 2024.
- A 5-year average of -$1529.4 and a median of -$20000.0 in 2024 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2023 and 2025: Change in Account Payables soared 3560.61% in 2023, then tumbled 1475.0% in 2025.
- Over 5 years, Change in Account Payables stood at $33000.0 in 2022, then jumped by 3560.61% to $1.2 million in 2023, then slumped by 63.91% to $436000.0 in 2024, then sank by 53.44% to $203000.0 in 2025, then jumped by 86.7% to $379000.0 in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered $379000.0, $203000.0, and -$315000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Pulmatrix | 5.46 Mn | 5.46 Mn | - | -122,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -122,000.00 |
| Jun 30, 2026 | -122,000.00 |
| Mar 31, 2026 | 379,000.00 |
| Mar 31, 2026 | 379,000.00 |
| Dec 31, 2025 | 203,000.00 |
| Dec 31, 2025 | 203,000.00 |
| Sep 30, 2025 | -315,000.00 |
| Sep 30, 2025 | -315,000.00 |
| Jun 30, 2025 | -273,000.00 |
| Jun 30, 2025 | -273,000.00 |
| Mar 31, 2025 | -152,000.00 |
| Mar 31, 2025 | -152,000.00 |
| Dec 31, 2024 | 436,000.00 |
| Dec 31, 2024 | 436,000.00 |
| Sep 30, 2024 | -20,000.00 |
| Sep 30, 2024 | -20,000.00 |
| Jun 30, 2024 | -328,000.00 |
| Jun 30, 2024 | -328,000.00 |
| Mar 31, 2024 | -1.19 Mn |
| Mar 31, 2024 | -1.19 Mn |